Cargando…

Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer

PURPOSE: The US Food and Drug Administration has recently granted accelerated approval of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib as treatment for men with metastatic castration-resistant prostate cancer (mCRPC) associated with a deleterious germline or somatic BRCA1 or BRCA2 (BRC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Labadie, Brian W, Morris, David S, Bryce, Alan H, Given, Robert, Zhang, Jingsong, Abida, Wassim, Chowdhury, Simon, Patnaik, Akash
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Perspectives
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860352/ https://www.ncbi.nlm.nih.gov/pubmed/35210863 http://dx.doi.org/10.2147/CMAR.S335962

Ejemplares similares

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
por: Abida, Wassim, et al.
Publicado: (2020)

A Case Study of Clinical Response to Rucaparib in a Patient with Metastatic Castration-Resistant Prostate Cancer and a RAD51B Alteration
por: Sautois, Brieuc, et al.
Publicado: (2022)

Rucaparib for metastatic castration-resistant prostate cancer: did TRITON3 deliver a trifecta?
por: Elias, Roy, et al.
Publicado: (2023)

Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance
por: Lorusso, Domenica, et al.
Publicado: (2020)

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
por: Fizazi, Karim, et al.
Publicado: (2022)

Emerging treatment options for ovarian cancer: focus on rucaparib
por: Mariappan, Lavanya, et al.
Publicado: (2017)

Targeted treatment of advanced ovarian cancer: spotlight on rucaparib
por: Pearre, Diana C, et al.
Publicado: (2018)

Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer
por: Zhang, Jingsong, et al.
Publicado: (2017)

Role of Rucaparib in the Treatment of Prostate Cancer: Clinical Perspectives and Considerations
por: Wu, Maximillian S, et al.
Publicado: (2022)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib
por: Liao, Mingxiang, et al.
Publicado: (2022)

Clinical significance of completion of radium-223 treatment and acute adverse events in patients with metastatic castration-resistant prostate cancer
por: Takeda, Kazuya, et al.
Publicado: (2023)

Encouraging probiotics for the prevention and treatment of immune-related adverse events in novel immunotherapies against malignant glioma
por: Yoshikawa, Sayuri, et al.
Publicado: (2022)

Radium-223 dichloride: illustrating the benefits of a multidisciplinary approach for patients with metastatic castration-resistant prostate cancer
por: Renzulli, Joseph F, et al.
Publicado: (2015)

Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)

An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
por: Nile, Donna L., et al.
Publicado: (2016)

Are Residents' Extended Shifts Associated With Adverse Events?
por: Szklo-Coxe, Mariana
Publicado: (2006)

Tuberculosis of spine: Research evidence to treatment guidelines
por: Jain, Anil K
Publicado: (2016)

Understanding adverse events of immunotherapy: A mechanistic perspective
por: Burke, Kelly P., et al.
Publicado: (2020)

Evaluation of phototoxicity induced by the anticancer drug rucaparib
por: Mateos-Pujante, Alejandro, et al.
Publicado: (2022)

Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study
por: Yubero, Alfonso, et al.
Publicado: (2022)

Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program
por: Yubero, Alfonso, et al.
Publicado: (2023)

Russian guidelines for the management of COPD: algorithm of pharmacologic treatment
por: Aisanov, Zaurbek, et al.
Publicado: (2018)

Ipilimumab in the treatment of metastatic melanoma: management of adverse events
por: Della Vittoria Scarpati, Giuseppina, et al.
Publicado: (2014)

Sick Children Crying for Help: Fostering Adverse Event Reports
por: Schiff, Gordon D.
Publicado: (2017)

Rucaparib as a Salvage Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma: A Case Report
por: Biswas, Ghanashyam
Publicado: (2022)

Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer
por: Adashek, Jacob J., et al.
Publicado: (2019)

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors
por: Shapiro, Geoffrey I., et al.
Publicado: (2018)

“Late You Come: Legislation on Lyme Treatment in an Era of Conflicting Guidelines”
por: Naktin, Jaan Peter
Publicado: (2017)

Under-Reporting of a Critical Perioperative Adverse Event: Intravenous Infiltration and Extravasation
por: Tewfik, George
Publicado: (2020)

Treatment sequencing in metastatic castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Guidelines for clinical diagnosis and treatment of osteonecrosis of the femoral head in adults (2019 version)
por: Zhao, Dewei, et al.
Publicado: (2020)

Association of TP53 clonal hematopoiesis with indeterminate potential with the development of myeloid neoplasms after rucaparib treatment
por: Yoshida, Reiko, et al.
Publicado: (2022)

Correction: Rucaparib as a Salvage Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma: A Case Report
por: Biswas, Ghanashyam
Publicado: (2022)

Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer
por: Campora, Sara, et al.
Publicado: (2016)

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy
por: Dal Molin, Graziela Z., et al.
Publicado: (2018)

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
por: Laroche, Audrey, et al.
Publicado: (2017)

Imaging PARP with [(18)F]rucaparib in pancreatic cancer models
por: Chan, Chung Ying, et al.
Publicado: (2022)

Development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment
por: Shankar, Abhishek, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jbtmntrpm4jpjvh47bj0nj4ani